Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women

Vaccine

Volumn 31, Issue 1, 2012, Pages 234-241

  Moscicki, A B ^a   Wheeler, C M ^b   Romanowski, B ^c   Hedrick, J ^d   Gall, S ^e   Ferris, D ^f   Poncelet, S ^g   Zahaf, T ^g   Moris, P ^g   Geeraerts, B ^g   Descamps, D ^g   Schuind, A ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Kentucky Pediatric Research Institute   (United States)

^e University of Louisville School of Medicine   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g GSK   (Belgium)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Anamnestic response; Cervical cancer; HPV infection; HPV vaccine; Sustained immunity

Indexed keywords

CD4 ANTIGEN; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MEMORY CELL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADOLESCENT; ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84870532430     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.037     Document Type: Article

References (29)

1. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.-N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
2. Naud P, Roteli-Martins CM, De Carvalho N, Teixeira J, Sanchez N, Zahaf T, et al. HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. In: Programs and abstracts of the 27th international papillomavirus conference and clinical workshop. September 17-22 (Berlin), Germany, 2011 [abstract O-18.04].
3. Roteli-Martins C.M., Naud P., De Borba P., Teixeira J.C., De Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin 2012, 8:1-8.
4. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
5. Christensen N.D., Reed C.A., Cladel N.M., Han R., Kreider J.W. Immunisation with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996, 70:960-965.
6. World Health Organization Human papillomavirus and HPV vaccines: technical information for policy-makers and health professional 2007, Available at:, [accessed 2 August 2010]. http://www.who.int/reproductivehealth/publications/cancers/IVB_07.05/en/.
7. Einstein M.H., Schiller J.T., Viscidi R.P., Strickler H.D., Coursaget P., Tan T., et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9:347-356.
8. Harper D.M., Franco E.L., Wheeler C.M., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
9. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.-B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
10. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985. The GlaxoSmithKline Vaccine HPV-007 Study Group.
11. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.-P.M., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008, 4:425-434.
12. Pastrana D.V., Buck C.B., Pang Y.-Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
13. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5:705-719.
14. Schwarz T.F., Kocken M., Petäjä T., Einstein M., Spaczynski M., Louwers J.A., et al. Correlation between levels of human papillomavirus (HPV)-16 and -18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin 2010, 6:1054-1061.
15. A induces cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011, 31:443-454.
16. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morell S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
17. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
18. Frentsch M., Arbach O., Kirchhoff D., Moewes B., Worm M., Rothe M., et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005, 11:1118-1124.
19. Chattopadhyay P.K., Yu J., Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005, 11:1113-1117.
20. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011, 7:1343-1358.
21. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
22. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000, 19:877-885.
23. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
24. Stanley M. Potential mechanisms for HPV vaccine-induced long-term memory protection. Gynecol Oncol 2010, 118:S2-S7.
25. Garçon N., Leo O. Innate immunity and vaccine adjuvants: from concepts to the development of a unique Adjuvant System AS04 used for the formulation of a human papillomavirus (HPV) vaccine. Curr Cancer Ther Rev 2010, 6:126-137.
26. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildersheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003, 95:1128-1137.
27. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007, 13:857-861.
28. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
29. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:320-340.